References
- Irving B, Davis C, Brock D, et al. Effect of exercise training intensity on abdominal visceral fat and body composition. Med Sci Sports Exerc. 2008;40(11):1863–1872.
- Church T, Thomas D, Tudor-Locke C et al. Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. PLoS One. 2011;6(5):e19657.
- Manson J, Hu F, Rich-Edwards J, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med. 1999;341(9):650–658.
- Turner N, Cooney G, Kraegen E, et al. Fatty acid metabolism, energy expenditure and insulin resistance in muscle. J Endocrinol. 2014;220:T61–T79.
- Pedersen B, Febbraio M. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8:457–465.
- Ahima R, Park. Connecting Myokines and Metabolism. Endocrinol Metab. 2015;30(3):235–245.
- McPherron A, Lawler A, Lee S. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature.1997;387(6628):83–90.
- Rodgers B, Garikipati D. Clinical, agricultural, and evolutionary biology of myostatin: a comparative review. Endocr Rev. 2008;29(5):513–534.
- Guo T, Bond N, Jou W, et al. Myostatin inhibition prevents diabetes and hyperphagia in a mouse model of lipodystrophy. Diabetes. 2012;61(10):2414–2423.
- Zhang C, McFarlane C, Lokireddy S, et al. Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia. 2011;54(6):1491–501.
- Wilkes JJ, Lloyd DJ, Gekakis N. Loss-of-function mutation in myostatinreduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance. Diabetes. 2009;58(5):1133–1143.
- Chen Y, Ye J, Cao L, et al. Myostatin regulates glucose metabolism via the AMP-activated protein kinase pathway in skeletal muscle cells. Int J Biochem Cell Biol. 2010;42(12):2072–2081.
- World Health Organization. WHO STEPS Surveillance Manual: The WHO STEPwise Approach to Chronic Disease Risk Factor Surveillance. 2005;Geneva: WHO. Available from http://www.who.int/ncd_surveillance/en/
- American Diabetes Association (2013). Diabetes Care. 2013;36(Suppl.1):S11–S66. Available from http://care.diabetesjournals.org/content/36/Supplement_1/S11.full
- Alberti K, Eckel R, Grundy S, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Circulation. 2009;120(16);1640–1645.
- Bonora E, Kiechl S, Willeit J, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes.1998;47(10):1643–1649.
- Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.
- Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(3):725–731.
- Tankova T, Chakarova N, Atanassova I, Dakovska L. Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucose tolerance and undetected diabetes. Diabetes Res Clin Pract. 2011;92(1):46–52.
- García-Fontana, Reyes-García R, Morales-Santana S, et al. Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state? Endocrine. 2016;52(1):54–62.
- Brandt C, Nielsen AR, Fischer CP, et al. Plasma and Muscle Myostatin in Relation to Type 2 Diabetes. PLoS ONE. 2012;7(5):e37236.
- Wang F, Liao Y, Li X, et al. Increased circulating myostatin in patients with type 2 diabetes mellitus. J Huazhong Univ Sci Technolog Med Sci. 201232(4):534–9.
- Han D, Chu-Su Y, Chiang C, et al. Serum Myostatin Is Reduced in Individuals with Metabolic Syndrome. PLoS ONE. 2014;9(9):e108230.
- Hittel DS, Axelson M, Sarna N, et al. Myostatin Decreases with Aerobic Exercise and Associates with Insulin Resistance. Med Sci Sports Exerc. 2010;42(11):2023–2029.
- Kazemi F. The correlation of resistance exercise-induced myostatin with insulin resistance and plasma cytokines in healthy young men. J Endocrinol Invest. 2016;39(4):383–388.
- Ryan AS, Li G, Blumenthal JB, Ortmeyer HK. Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults. Obesity (Silver Spring). 2013;21(7):1350–1356.
- Williams N, Interlichia J, Jackson M, et al. Endocrine Actions of Myostatin: Systemic Regulation of the IGF and IGF Binding Protein Axis. Endocrinology. 2011;152(1):172–180.